Skip to content

Impact of Hip Flexors Isokinetic Strengthening on Gait Capacities in Subacute Stroke Patients

Impact of Hip Flexors Isokinetic Strengthening on Gait Capacities in Subacute Stroke Patients

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02917850
Acronym
ISOKINETIC
Enrollment
0
Registered
2016-09-28
Start date
2016-08-31
Completion date
2018-07-31
Last updated
2018-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gait, Hemiplegia, Stroke

Keywords

stroke, gait, hip flexors, paresis, hemiplegia

Brief summary

Post-stroke patients often present with gait disorders due to several physical impairments. Hip flexor deficit is one of the more prevalent trouble and is associated with gait capacities. This study aims at evaluating the impact of an isokinetic hip flexors strengthening rehabilitation program in the subacute phase after stroke. Patients will be randomized to an intervention group (isokinetic rehabilitation) or a control group (conventional rehabilitation) and assessed at the end of the rehabilitation program, at 3 and at 6 months.

Interventions

PROCEDUREIsokinetic hip flexors strengthening

Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.

PROCEDUREConventional rehabilitation

Conventional rehabilitation 10/w during 6 weeks

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients suffering from a first ever stroke * At the subacute phase * Able to walk at least 10m with or without assistive devices * Hip flexors strength on the paretic side \> 2/5 (MRC)

Exclusion criteria

* Uncontrolled epilepsy * Contraindications to physical activity (severe arterial hypertension, aortic valvulopathy, severe PAD...) * History of muscular or joint disorders on the paretic hip * Subject unable to deliver an informed written consent (due to aphasia, cognitive or psychiatric disorders...) * Protected persons * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Max gait speed (m/s)6 weeksGait speed will be assessed in the 10m walk test

Secondary

MeasureTime frameDescription
Hip flexors strength6weeks; 3 and 6 monthsHip flexors strength will be evaluated using an isokinetic dynamometer (concentric, 30°/s) and motor testing (medical research council)
Gait endurance6 weeks; 3 and 6 monthsGait endurance will be assessed using the 6MWT
Max gait speed (m/s)3 and 6 monthsGait speed will be assessed in the 10m walk test
Balance and postural control6 weeks; 3 and 6 monthsPostural Assessment for Stroke Scale (PASS)
Rate of perceived exhaustion during gait6 weeks; 3 and 6 monthsBorg scale
Gait capacities6 weeks; 3 and 6 monthsFunctional ambulation categories (FAC)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026